risankizumab vs SPY003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.

Next expected readout: August 2027 · NCT06880744 (registry estimate)

Reported efficacy

clinical remission + endoscopic improvement met (met)

Result source: INSPIRE/COMMAND

SPY003

Developed by Spyre Therapeutics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23)
Partial signal

NCT07012395 · Phase 2 · recruiting

This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: June 2027 · NCT07012395 (registry estimate)

Reported efficacy

Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)

Result source: NCT07012395

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointrisankizumabSPY003
Clinical remission (induction)20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
—Not reported
Clinical remission (maintenance)—Trial running · NCT03398135—Not reported
Clinical response (induction)64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
—Not reported
Endoscopic improvement (induction)36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT03398135—Not reported

Clinical remission (induction)

risankizumab
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
SPY003
—Not reported

Clinical remission (maintenance)

risankizumab
—Trial running · NCT03398135
SPY003
—Not reported

Clinical response (induction)

risankizumab
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
SPY003
—Not reported

Endoscopic improvement (induction)

risankizumab
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
SPY003
—Not reported

Corticosteroid-free remission (maintenance)

risankizumab
—Trial running · NCT03398135
SPY003
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SPY003
Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). NCT07012395 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. risankizumab: 4 of 4 rows · SPY003: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
4.9%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.8%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Discontinued due to AEs
3.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
0%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
3.3%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Serious AEs
6.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
2.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.5%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.9%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.4%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.5%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.6%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.7%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Most frequent reported AEs
1200 mg IV
colitis ulcerative 4.9% (placebo 8.5%)
headache 4.9% (placebo 5.1%)
nasopharyngitis 4.9% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 12 more results
1200 mg IV
covid-19 4.6% (placebo 0%)
anaemia 3.2% (placebo 3.4%)
headache 2.9% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.9% (placebo 0%)
headache 2.9% (placebo 5.1%)
anaemia 1.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.7% (placebo 0%)
anaemia 2.9% (placebo 3.4%)
colitis ulcerative 1.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
nasopharyngitis 8.5% (placebo 6.8%)
headache 7% (placebo 5.1%)
colitis ulcerative 4.2% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
anaemia 8.5% (placebo 3.4%)
covid-19 8.5% (placebo 0%)
headache 8.5% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
headache 2.8% (placebo 5.1%)
anaemia 1.4% (placebo 3.4%)
nasopharyngitis 1.4% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
covid-19 5.6% (placebo 0%)
colitis ulcerative 4.2% (placebo 8.5%)
anaemia 2.8% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 8.6% (placebo 6.8%)
headache 6.9% (placebo 5.1%)
anaemia 1.7% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 7% (placebo 6.8%)
headache 6.5% (placebo 5.1%)
anaemia 3.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 10.8% (placebo 6.8%)
anaemia 2.7% (placebo 3.4%)
colitis ulcerative 2.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
dry skin 5.6% (placebo 0%)
headache 5.6% (placebo 5.1%)
nasopharyngitis 5.6% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
600 mg IV
nasopharyngitis 8.1% (placebo 6.8%)
bronchitis 6.5% (placebo 0%)
dry skin 3.2% (placebo 0%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

Clinical Remission 9.8% (n=61) vs 1.7% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
show 4 more results
20.3% (n=650) vs 6.2% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3% (n=58) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
12.4% (n=340) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 42 Participants as posted
11.5% (n=61) vs 1.7% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
Endoscopic Improvement 13.1% (n=61) vs 5% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 8 Participants as posted
show 3 more results
15.5% (n=58) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 9 Participants as posted
17.9% (n=340) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 61 Participants as posted
24.6% (n=61) vs 5% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 15 Participants as posted
Clinical Response 45.9% (n=61) vs 20% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
show 9 more results
45.9% (n=61) vs 25% (n=60) placebo @ 4wk*1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
64.3% (n=650) vs 35.7% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
52.2% (n=650) vs 30.5% (n=325) placebo @ 4wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
53.4% (n=58) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 31 Participants as posted
46.2% (n=340) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 157 Participants as posted
37.9% (n=58) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
43.5% (n=340) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 148 Participants as posted
42.6% (n=61) vs 20% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 26 Participants as posted
32.8% (n=61) vs 25% (n=60) placebo @ 4wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 20 Participants as posted
Endoscopic Remission 4.9% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
show 4 more results
10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
UC-related Hospitalization 6.6% (n=61) vs 8.3% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 4 Participants as posted
show 3 more results
5.2% (n=58) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
5.6% (n=340) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 19 Participants as posted
9.8% (n=61) vs 8.3% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
HEMR 3.3% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 2 Participants as posted
show 3 more results
1.7% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
2.9% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 10 Participants as posted
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
UC-SQ -15.6 vs -7.4 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
-15.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-17.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-13.8 vs -7.4 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
IBDQ 40.3 vs 20.1 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
42.6 vs 24.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
40 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
49.5 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
37.4 vs 20.1 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 PCS 6.35 vs 3.904 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
6.296 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.719 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.112 vs 3.904 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 MCS 7.284 vs 3.094 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
5.442 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.777 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
6.756 vs 3.094 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9 vs 3.7 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
7.9 vs 3.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.7 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.6 vs 3.7 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
UC-related Surgery 0% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
2.1% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
1.6% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · SPY003's landscape